Bergur V. Stefánsson

Author

Also Known As

B STEFANSSON, B Stefánsson, B V Stefansson, B. Stefansson, B.V. Stefánsson, BERGUR STEFANSSON, Bergur Stefansson, Bergur Stefánsson, Bergur V Stefansson, Bergur V Stefánsson

Publications

9.4K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (Sweden)University Medical Center Groningen University of Groningen University College London University of Copenhagen

About

Bergur V. Stefánsson is an author at AstraZeneca (Sweden) specializing in medicine, diabetes, and chronic kidney disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	1.2K
2	Health Sciences	2	2	64
3	Engineering	1	1	11
4	Public Health	1	1	53
5	Chemical Engineering	1	1	11

Bergur V. Stefánsson

Publications

8.5K

Citations

H-Index

Page 1

	Year	Citations
Dapagliflozin in Patients with Chronic Kidney Disease Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter, New England Journal of Medicine	2020	4.8K
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, The Lancet Diabetes & Endocrinology Metabolic SyndromeHypertensionRenal FunctionRenal DiseaseCardiovascular Disease	2020	498
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, Kidney International	2021	369
Intradialytic Hypotension and Risk of Cardiovascular Disease Bergur V. Stefánsson, Steven M. Brunelli, Claudia Cabrera, Clinical Journal of the American Society of Nephrology	2014	316
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial Hiddo J.L. Heerspink, Bergur V. Stefánsson, Glenn M. Chertow, Nephrology Dialysis Transplantation	2019	211
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial Carol A. Pollock, Bergur V. Stefánsson, Daniel Reyner, The Lancet Diabetes & Endocrinology Metabolic SyndromeDiabetes ManagementRenal FunctionRenal DiseaseAlbuminuria-lowering Effect	2019	194
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial Niels Jongs, Tom Greene, Glenn M. Chertow, The Lancet Diabetes & Endocrinology UrologyRenal DiseaseRenal FunctionKidney FailureDiabetes	2021	187
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial Hiddo J.L. Heerspink, Niels Jongs, Glenn M. Chertow, The Lancet Diabetes & Endocrinology Metabolic SyndromeRenal FunctionRenal DiseaseKidney FailureDiabetes	2021	181
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics David C. Wheeler, Bergur V. Stefánsson, Oleksandr Bilchenko, Nephrology Dialysis Transplantation	2020	180
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease John J.V. McMurray, David C. Wheeler, Bergur V. Stefánsson, Circulation	2020	138

Page 1